Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OpGen, Inc.
  6. News
  7. Summary
    OPGN   US68373L3078


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OPGEN INC : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)

10/15/2021 | 04:33pm EST

Item 1.01. Entry Into a Material Definitive Agreement.

Securities Purchase Agreement

On October 13, 2021, OpGen, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with a institutional investor (the "Investor"), pursuant to which the Company agreed to issue and sell to the Investor in a registered direct offering (the "Offering") (i) 150,000 shares of the Company's Series B Convertible Preferred Stock (the "Preferred Stock"), par value $0.01 per share (the "Preferred Stock"), and (ii) 7,500,000 warrants (the "Common Warrants") to purchase an aggregate of 7,500,000 shares of the Company's common stock ("Common Stock"). The shares of Preferred Stock will have a stated value of $100 per share and are convertible into an aggregate of 7,500,000 shares of Common Stock at a conversion price of $2.00 per share at any time after the Company receives stockholder approval to increase the number of authorized shares of Common Stock of the Company. The Company expects to receive aggregate gross proceeds from the Offering of $15 million before deducting the placement agent's fees and the Company's Offering expenses. The Offering is expected to close on or about October 18, 2021, subject to satisfaction of customary closing conditions.

In connection with the Offering and in accordance with the Purchase Agreement, the Company plans to call a special meeting of stockholders to consider the following two proposed amendments (the "Proposals") to the Company's Certificate of Incorporation, as amended (the "Charter"): (i) an amendment to the Charter to reduce the stockholder approval requirement for changes to the Charter and bylaws to a majority of the outstanding shares entitled to vote; and (ii) an amendment to the Charter to increase the authorized number of shares of capital stock from 60,000,000 shares to 110,000,000 and the authorized number of shares of Common Stock from 50,000,000 to 100,000,000 shares. The Investor has agreed in the Purchase Agreement to vote the shares of Preferred Stock purchased in the Offering in favor of such Proposals.

Pursuant to the Purchase Agreement, the Company will file a certificate of designation (the "Certificate of Designation") with the Secretary of State of Delaware designating the rights, preferences and limitations of the shares of Preferred Stock. The Certificate of Designation will provide, in particular, that the Preferred Stock will have no voting rights, other than the right to vote as a class on certain matters, except that each share of Preferred Stock will have the right to cast 30,000 votes per share of Preferred Stock on the Proposals; provided, that with respect to the proposal to increase the authorized shares of Common Stock and in accordance with Nasdaq listing rules, the votes cast by the holder of the Preferred Stock must be counted by the Company in the same proportion as the aggregate shares of Common Stock voted on this proposal.

The holder of Preferred Stock will be entitled to dividends, on an as-if converted basis, equal to dividends actually paid, if any, on shares of Common Stock. The Preferred Stock is convertible into shares of Common Stock at a rate of $2.00 per share. The conversion price can be adjusted pursuant to the Certificate of Designation for stock dividends and stock splits, subsequent rights offerings, pro rata distributions of dividends or the occurrence of a fundamental transaction (as defined in the Certificate of Designation). The Preferred Stock can be converted at the option of the holder at any time after the Company has received stockholder approval for the amendment to increase its authorized shares of Common Stock. In addition, following the receipt of stockholder approval for such amendment, and subject to the satisfaction of certain conditions, the Company can cause the holder of the Preferred Stock to convert their shares of Preferred Stock; provided, that shares of Preferred Stock cannot be converted to Common Stock if the holder would beneficially own in excess of 9.99% of the Company's outstanding Common Stock.

The Common Warrants will have an exercise price of $2.05 per share, will be exercisable on the later of the date of stockholder approval and six months following the date of issuance, and will expire five years following the initial exercise date. The exercise price and the number of shares of Common Stock issuable upon exercise of each Common Warrant is subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of Warrants will be entitled to receive, upon exercise of the Common Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Common Warrants immediately prior to the fundamental transaction? provided, however, that in the event of a fundamental transaction where the consideration consists solely of cash, solely of marketable securities or a combination thereof, each Common Warrant will be deemed to be exercised in full in a cashless exercise effective immediately prior to and contingent upon the consummation of such fundamental transaction.

The Company may not effect the exercise of certain Common Warrants, and the applicable holder will not be entitled to exercise any portion of any such Common Warrant, which, upon giving effect to such exercise, would cause the aggregate number of shares of Common Stock beneficially owned by the holder of such Common Warrant (together with its affiliates) to exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the . . .

Item 3.03. Material Modifications to Rights of Security Holders.

The disclosure required by this Item and included in Item 1.01 of this Current Report is incorporated herein by reference.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

The disclosure required by this Item and included in Item 1.01 of this Current Report is incorporated herein by reference.

In addition, on October 15, 2021, pursuant to Section 7.02 of the Amended and Restated Bylaws (as amended, the "Bylaws") of the Company, the board of directors of the Company adopted an amendment to the Bylaws (the "Amendment"), effective as of October 15, 2021. The Amendment is intended to clarify the determination of a quorum for any meeting of the stockholders.

Item 8.01. Other Events.

On October 14, 2021, the Company issued a press release announcing the Offering and the entry into the Purchase Agreement. A copy of such press release is attached to this Current Report on Form 8-K as Exhibits 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed herewith:

3.1         Form of Certificate of Designation of Preferences, Rights and
          Limitations of Series B Convertible Preferred Stock.
3.2         Amendment to Amended and Restated Bylaws, as amended, effective
          October 15, 2021.
4.1         Form of Common Stock Purchase Warrant.
5.1         Opinion of Ballard Spahr LLP.
10.1        Form of Securities Purchase Agreement, dated October 13, 2021 by and
          between OpGen, Inc. and the purchaser party thereto.
23.1        Consent of Ballard Spahr LLP (included in Exhibit 5.1).
99.1        Press release dated October 14, 2021.
104       Cover Page Interactive Data File (embedded within the Inline XBRL

© Edgar Online, source Glimpses

All news about OPGEN, INC.
04:31pOPGEN : Subsidiary Ares Genetics Announces Strategic Database Access Transaction - Form 8-..
04:20pOPGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
08:46aOpGen Subsidiary Ares Genetics Announces Strategic Database Access Transaction
11/12OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update - Form ..
11/11OpGen, Inc. Provides Revenue Guidance for the Year 2021
11/11Earnings Flash (OPGN) OPGEN Reports Q3 Revenue $1.2M, vs. Street Est of $1.2M
11/11OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update
11/11OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
11/04OpGen Corporate Presentation (PDF)
11/04OpGen Appoints Albert Weber as Chief Financial Officer - Form 8-K
More news
Analyst Recommendations on OPGEN, INC.
More recommendations
Financials (USD)
Sales 2021 3,80 M - -
Net income 2021 -35,9 M - -
Net cash 2021 8,88 M - -
P/E ratio 2021 -1,55x
Yield 2021 -
Capitalization 60,0 M 60,0 M -
EV / Sales 2021 13,5x
EV / Sales 2022 8,98x
Nbr of Employees 102
Free-Float 99,7%
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,54 $
Average target price 4,18 $
Spread / Average Target 171%
EPS Revisions
Managers and Directors
Oliver Schacht President, Chief Executive Officer & Director
William E. Rhodes Non-Executive Chairman
Vadim Sapiro Chief Information Officer
Faranak Atrzadeh Chief Marketing & Scientific Affairs Officer
Johannes Bacher Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
OPGEN, INC.-24.51%60
MODERNA, INC.252.74%149 412
LONZA GROUP AG28.41%58 671
SEAGEN INC.-5.61%30 228
CELLTRION, INC.-42.34%24 321